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Phosphatemic effect of cinacalcet in kidney transplant recipients
with persistent hyperparathyroidism
Abstract
BACKGROUND: In kidney transplant recipients, persistent hyperparathyroidism leads to
hypercalcemia and increased urinary phosphorus excretion. The calcimimetic drug cinacalcet effectively
decreases parathyroid hormone (PTH) levels and corrects hypercalcemia in these patients. The purpose
of the present study is to examine the effect of cinacalcet treatment on determinants of renal phosphorus
reabsorption under steady-state conditions. STUDY DESIGN: Open-label prospective uncontrolled trial.
SETTING & PARTICIPANTS: 10 stable kidney transplant recipients with persistent
hyperparathyroidism. INTERVENTION: Cinacalcet, 30 and 60 mg/d, for 2 weeks. OUTCOMES &
MEASURES: Changes in urinary phosphorus excretion in timed urine samples, intact and
carboxy-terminal (C-term) fibroblast growth factor 23 (FGF-23), intact PTH, venous pH, and
bicarbonate values at defined intervals over 24 hours. RESULTS: Cinacalcet decreased renal
phosphorus excretion in the first 8 hours by 30% to 40%, but not from 8 to 24 hours after drug
administration. Serum phosphorus levels normalized in all patients. Cinacalcet markedly decreased
plasma intact PTH levels (60%; P < 0.001). Cinacalcet also decreased mean intact FGF-23 levels from
67 +/- 8 (SE) to 51 +/- 5 and to 54 +/- 6 pg/mL (P < 0.001) and mean C-term FGF-23 levels from 108
+/- 15 to 87 +/- 9 and to 101 +/- 9 RU/mL (P < 0.01), respectively. There was high correlation between
intact FGF-23 and C-term FGF-23 levels (r = 0.598; P < 0.001). Acid-base status was unchanged.
LIMITATIONS: This is a small study and does not examine the long-term effect of cinacalcet treatment.
CONCLUSIONS: Cinacalcet effectively corrected urinary phosphate wasting in kidney transplant
recipients, resulting in normalization of serum phosphorus levels. The phosphatemic effects of
cinacalcet correlated with a marked decrease in the phosphaturic hormone PTH, rather than with a
change in FGF-23 levels or acid-base status, highlighting the importance of PTH in posttransplantation
hypophosphatemia.
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Phosphatemic Effect of Cinacalcet in Kidney Transplant Recipients With
Persistent Hyperparathyroidism
Andreas L. Serra, MD,1,2 Claudia Wuhrmann, MSc,2 and Rudolf P. Wüthrich, MD1,2
Background: In kidney transplant recipients, persistent hyperparathyroidism leads to hypercalcemia
and increased urinary phosphorus excretion. The calcimimetic drug cinacalcet effectively decreases
parathyroid hormone (PTH) levels and corrects hypercalcemia in these patients. The purpose of the
present study is to examine the effect of cinacalcet treatment on determinants of renal phosphorus
reabsorption under steady-state conditions.
Study Design: Open-label prospective uncontrolled trial.
Setting & Participants: 10 stable kidney transplant recipients with persistent hyperparathyroidism.
Intervention: Cinacalcet, 30 and 60 mg/d, for 2 weeks.
Outcomes & Measures: Changes in urinary phosphorus excretion in timed urine samples, intact and
carboxy-terminal (C-term) fibroblast growth factor 23 (FGF-23), intact PTH, venous pH, and bicarbonate
values at defined intervals over 24 hours.
Results: Cinacalcet decreased renal phosphorus excretion in the first 8 hours by 30% to 40%, but not
from 8 to 24 hours after drug administration. Serum phosphorus levels normalized in all patients. Cinacalcet
markedly decreased plasma intact PTH levels (60%; P  0.001). Cinacalcet also decreased mean intact
FGF-23 levels from 67 8 (SE) to 51 5 and to 54 6 pg/mL (P 0.001) and mean C-term FGF-23 levels
from 108 15 to 87 9 and to 101 9 RU/mL (P 0.01), respectively. There was high correlation between
intact FGF-23 and C-term FGF-23 levels (r 0.598; P 0.001). Acid-base status was unchanged.
Limitations: This is a small study and does not examine the long-term effect of cinacalcet treatment.
Conclusions: Cinacalcet effectively corrected urinary phosphate wasting in kidney transplant recipients,
resulting in normalization of serum phosphorus levels. The phosphatemic effects of cinacalcet correlated
with a marked decrease in the phosphaturic hormone PTH, rather than with a change in FGF-23 levels or
acid-base status, highlighting the importance of PTH in posttransplantation hypophosphatemia.
Am J Kidney Dis 52:1151-1157. © 2008 by the National Kidney Foundation, Inc.
INDEX WORDS: Cinacalcet; hyperparathyroidism; parathyroid hormone (PTH); fibroblast growth factor
23 (FGF-23); phosphorus; renal transplantation.c
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Zn kidney transplant recipients, persistent hyper-
parathyroidism caused by excessive secretion
f parathyroid hormone (PTH) causes hypercalce-
ia and increased urinary phosphorus excretion.
he amount of renal phosphorus excretion is deter-
ined largely by glomerular filtration and tubular
eabsorption. PTH decreases renal phosphorus reab-
orption through internalization of the tubular type
a sodium-phosphate transporter and by decreasing
ype 2a sodium-phosphate transporter gene tran-
cription.1,2 The recently described bone hormone
broblast growth factor 23 (FGF-23) decreases
hosphorus reabsorption through changes in the
ype 2a sodium-phosphate transporter and sup-
resses 1-hydroxylase activity in the kidney.3,4
irculating FGF-23 levels are increased in
atients with primary,5,6 secondary,7-9 and per-
istent hyperparathyroidism10,11 and contrib-
te to the development of early posttransplan-
ation hypophosphatemia.12
Calcimimetics decrease PTH production and
ecretion by increasing the sensitivity of the
merican Journal of Kidney Diseases, Vol 52, No 6 (December), 2alcium-sensing receptor to calcium on chief
ells of the parathyroid gland.13 Cinacalcet is a
alcimimetic agent approved for treatment of
atients with primary and secondary hyperpara-
hyroidism. We and others have examined the
ffect of cinacalcet in kidney transplant recipi-
nts with persistent hyperparathyroidism and
hown that cinacalcet treatment decreased serum
alcium and PTH levels.14,15 Interestingly, most,
ut not all, studies reported that cinacalcet also
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Serra, Wuhrmann, and Wüthrich1152ncreased phosphorus levels in such patients.14-18
e recently studied the correlation of steady-state
harmacokinetics with the pharmacodynamic ef-
ects of cinacalcet in 10 kidney transplant recipi-
nts with persistent hyperparathyroidism and
howed that cinacalcet dose-dependently decreased
onized serum calcium levels and increased urinary
alcium excretion significantly in the first 8 hours
fter administration of 60 mg of cinacalcet. Kidney
unction assessed by using measured creatinine
learance (46 mL/min 1.73 m2) was stable (creati-
ine clearance in mL/min/1.73 m2 may be con-
erted to mL/s/1.73 m2 by multiplying by 0.01667).
,25-Dihydroxyvitamin D3 and 25-hydroxyvita-
in D3 levels remained in the normal range.17 The
urpose of the present study is to examine the effect
f cinacalcet treatment on determinants of renal
hosphorus reabsorption in these 10 patients, in
articular on the phosphatonin FGF-23. The im-
rovement in urinary phosphate wasting appears to
esult from a cinacalcet-mediated decrease in PTH
evels, rather than an effect of the phosphaturic
ormone FGF-23 or acid-base status, highlighting
he importance of PTH in posttransplantation hy-
ophosphatemia.
METHODS
Ten kidney transplant recipients with persistent hyperpara-
hyroidism and stable allograft function were studied. The
ocal ethics committee approved the study, and all patients
ave their written informed consent. The study design and
arts of the results have been published elsewhere.17 Briefly,
inacalcet was administrated at 30 mg/d for 2 weeks, fol-
owed by another 2 weeks with 60 mg/d. Patients were
tudied under steady-state conditions at the end of each
-week treatment period. On the morning of the study days
nd after overnight fasting, blood samples were drawn from
forearm vein through an intravenous catheter at 8:00 AM
study time 0 hours) and at various times thereafter until
:00 AM the following day. Cinacalcet was administered at
:00 AM after the first blood sampling. Phosphorus excretion
as measured in 2 timed urine samples collected between
:00 AM and 4:00 PM (8-hour sample) and 4:00 PM and 8:00
M (16-hour sample) the following day.
After the 8:00 AM blood collection, patients had a standard-
zed breakfast (120 g of scrambled eggs, 2 slices of toasted
hite bread, 1 tablespoon of fruit preserve, 1 tablespoon of
argarine, 60 g of melon, 120 g of apple juice) containing
pproximately 300 mg of phosphorus and 120 mg of cal-
ium. At noon, they ingested a light meal, and supper was
ree choice.
aboratoryAnalysis
Intact FGF-23 (Kainos Laboratories Inc, Tokyo, Japan)
nd carboxy-terminal (C-term) FGF-23 (Immutopics Inc, an Clemente, CA) were measured using specific enzyme-
inked immunosorbent assay kits according to the manufac-
urer’s protocol. Venous bicarbonate and pH were deter-
ined immediately after collection in electrolyte-balanced
eparin tubes (1 mL) using automated blood gas analysis
ABL 815 Flex; Radiometer, Copenhagen, Denmark). Phos-
horus and calcium were measured by using standard meth-
ds; creatinine, by using the Jaffé method; and plasma intact
TH (iPTH), by using a double-antibody chemilumines-
ence immunoassay (Roche Diagnostics, Basel, Switzer-
and). Deoxypyridinoline-creatinine ratio was determined in
he morning spot urine sample. All biochemical analyses
ere performed at the Department of Clinical Chemistry of
ur institution.
tatistical Analysis
Mean values for continuous data were compared by using
tudent t-test. All P values were 2 sided for comparison with
aseline values, and P less than 0.05 is considered statisti-
ally significant. Results are expressed as mean  SE.
earson correlation coefficient was used to test for associa-
ions between continuous variables. One-way analysis of
ariance for repeated measures with Bonferroni post hoc test
as used when analyzing time course profiles of iPTH,
ntact FGF-23, and C-term FGF-23.
RESULTS
Ten kidney transplant recipients (6 men and 4
omen aged 58.3  2.6 years) with stable graft
unction (glomerular filtration rate [GFR]  40
L/min/1.73 m2, estimated by using the Modifi-
ation of Diet in Renal Disease Study equation)
ere included in the study a median of 3.3 years
range, 0.8 to 31.3 years) after transplantation.
idney function was stable throughout the study.
he individual immunosuppressive regimens
ncluded cyclosporine (8 patients), mycopheno-
ate mofetil (6 patients), azathioprine (3 pa-
ients), prednisone (3 patients, all  10 mg/d),
nd tacrolimus (1 patient) and were unchanged
uring the study. Table 1 lists baseline labora-
ory data.
As shown in Fig 1, cinacalcet treatment in-
reased serum phosphorus levels dose depen-
ently and decreased the inappropriate increased
ractional excretion of phosphorus by approxi-
ately one-third in the first 8 hours after cinacal-
et administration. Fractional excretion of phos-
horus from 4:00 PM to 8:00 AM on the following
ay did not change. Urinary total phosphorus
xcretion in first 8 hours (17.5  3.2 to 10.9 
.0 to 16.5  2.9 mg; P  0.2) and the subse-
uent 16 hours (46.6 6.1 to 43.8 9.8 to 44.69.6 mg; P 0.5) was not changed by cinacal-
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Phosphatemic Effect of Cinacalcet 1153et treatment. Serum phosphorus levels re-
ained less than 4.5 mg/dL in all patients and at
ny sampling time. To elucidate whether the
inacalcet-induced decrease in phosphorus excre-
ion was associated with changes in hormones
hat influence phosphorus levels, we measured
TH and FGF-23 during the course of 24 hours
Table 1. Baseline Laborato
Parameters Normal Range
alcium (mg/dL) 8.4-10.2
ntact FGF-23 (pg/mL) 29.7  20.7*
arboxy-terminal FGF-23 (RU/mL) 72.9  38.2*
erum bicarbonate (mEq/L) 20-25
H 7.36-7.40
rinary deoxypyridinoline-creatinine
ratio (nmol/mmol) 2.5-9.5
Note: Calcium in mg/dL may be converted to mmol/L b
Eq/L and mmol/L are equivalent.
Abbreviation: FGF-23, fibroblast growth factor 23.
*Assay mean  SD value derived from 118 normophosp
Figure 1. Serum phosphorus levels and renal excre-
ion of phosphorus. (A) Serum phosphorus levels in-
reased 8 and 24 hours after cinacalcet administration. (B)
rinary phosphorus excretion in the first 8 hours was
ecreased by cinacalcet. Values shown as mean  SE.
wo-sided t-test, *P  0.05, **P  0.01. Note: Serum
hosphorus in mg/dL may be converted to mmol/L by
ultiplying by 0.3229. Abbreviation: FEPO4, fractional ex-
retion of filtered phosphate.
6
snder steady-state conditions. As previously
hown, at baseline, iPTH levels were increased
bout 4 times the upper normal level and cinacal-
et treatment decreased iPTH levels in the first 8
ours after dosing significantly by approxi-
ately 60% at nadir (Fig 2). Intact and C-term
GF-23 levels amounted to approximately twice
he upper limit of the normal range at baseline at
ime 0 hour. Treatment with 30 and 60 mg/d of
inacalcet for 2 weeks decreased intact FGF-23
evels from 67  8 to 51  5 and to 54  6
g/mL (P  0.001) and C-term FGF-23 levels
rom 108 15 to 87 9 and to 101 9 RU/mL
P  0.01), respectively (Fig 3). Intact FGF-23
evels had a tendency to increase after the sam-
ling at 8:00 AM. This kind of circadian rhythm
f intact FGF-23 levels also was seen during
inacalcet treatment and was less pronounced
a for the 10 Study Patients
Baseline Day 14 Day 28
10.1  0.2 9.3  0.3 8.5  0.4
67.2  8.5 51.4  4.5 54.1  7.7
108.1  14.6 87.3  8.5 100.8  13.9
22.2  0.2 21.9  0.8 22.4  0.8
7.33  0.04 7.33  0.01 7.34  0.01
11.1  2.5 10.6  2.2 10.5  1.4
plying by 0.2495. Serum bicarbonate levels expressed in
ic individuals.27
Figure 2. Time course profiles of percentage of change
n intact parathyroid plasma (iPTH) levels. Cinacalcet
ecreased iPTH levels, expressed as mean percentage of
aseline values (dotted line, values at day 0  0%) in the
rst 8 hours after administration of 30 (open triangle) andry Dat
y multi0 mg/d (closed square) of cinacalcet (P  0.001). Values
hown as mean SE.
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Serra, Wuhrmann, and Wüthrich1154ith C-term FGF-23. The variation in intact
GF-23 levels was smaller compared with C-term
GF-23, as shown by a tighter SD. Correlation
etween intact FGF-23 and C-term FGF-23 lev-
ls was high (r 0.598; P 0.001; Fig 4).
Cinacalcet treatment did not change acid-base
tatus, assessed by means of venous pH and
icarbonate level or urinary deoxypyridinoline-
reatinine ratio (Table 1).
DISCUSSION
Cinacalcet represents a promising therapeu-
ic agent to treat renal allograft recipients with
ersistent posttransplantation hyperparathy-
Figure 3. Intact and carboxy-terminal (C-term) fibro-
last growth factor 23 (FGF-23) level time course profiles.
A) Cinacalcet decreased intact FGF-23 (P  0.001) and
B) and C-term FGF-23 (P 0.0078) levels in the 24 hours
fter dosing. Values shown as mean SE.oidism with hypercalcemia. We and others
(
0ave shown that cinacalcet effectively de-
reases levels of the phosphaturic hormone
TH in such patients.14,15,17-21 The aim of the
resent study is to gain insight into the effect
f cinacalcet on determinants of renal phospho-
us reabsorption in kidney transplant patients
ith persistent hyperparathyroidism.
Renal allograft recipients with persistent hyper-
arathyroidism frequently show hypophospha-
emia and increased rates of fractional excretion
f phosphorus in the setting of stable graft func-
ion. The kidney is one of the major phosphorus-
andling organs, and administration of cinacal-
et for 2 weeks significantly decreased renal
hosphorus excretion and increased serum phos-
horus levels in our kidney transplant recipients
ith persistent hyperparathyroidism. A similar
hosphatemic action of cinacalcet was seen in
atients with stages 3 and 4 chronic kidney
isease (CKD) with secondary hyperparathyroid-
sm.22 In these patients, treatment with cinacal-
et decreased urinary phosphorus excretion by
pproximately 10%, resulting in a significant
ncrease in serum phosphorus levels from 4 to 5
g/dL. In our study, levels of both phosphaturic
ormones, PTH and FGF-23, were markedly
ncreased at baseline. Cinacalcet treatment was
ery effective in decreasing iPTH levels, whereas
ntact and C-term FGF-23 levels were only mod-
rately decreased. When PTH levels were low-
st, urinary phosphorus excretion was decreased,
lthough FGF-23 levels remained increased. Our
nding that renal phosphorus absorption signifi-
antly decreased in the presence of increased
Figure 4. Correlation between intact fibroblast growth
actor 23 (FGF-23; Kainos Inc) and carboxy-terminal
C-term) FGF-23 (Immunotopic Inc) levels (r  0.598; P 
.001). Line of linear regression is shown.
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Phosphatemic Effect of Cinacalcet 1155GF-23 levels indicates that the effect of these
hosphaturic hormones in renal phosphorus ab-
orption is dissociated and highlights the impor-
ance of PTH reduction in increasing serum
hosphorus levels in our patients. A similar situ-
tion is present in patients with tumor-induced
steomalacia (TIO). TIO, a rare acquired disease
f renal phosphate wasting, is caused by mesen-
hymal tumors that produce FGF-23. In these
atients, cinacalcet treatment decreased PTH and
enal phosphorus excretion despite unchanged
igh FGF-23 levels.23 In our study, the better
orrection of serum phosphorus level with the
igher cinacalcet dose did not result in a further
ecrease in FGF-23 levels, a finding that further
upports our hypothesis that PTH reduction has a
ajor role in the cinacalcet-mediated increase in
erum phosphorus concentration. Hence, the
hosphatemic action of cinacalcet appears to be
ediated mainly by the decrease in PTH levels,
nd the decrease in FGF-23 levels contributes
ess to the cinacalcet-mediated decrease in uri-
ary phosphorus excretion in kidney transplant
ecipients.
FGF-23 concentrations are increased in pa-
ients with CKD even before hyperphosphatemia
ppears, but the stimulus driving this increase is
nclear. It is attractive to postulate that FGF-23
ynthesis is induced by changes in serum phos-
horus levels in response to changes in dietary
hosphorus intake. However, in a recent study by
sakova et al24 of normophosphatemic and nor-
ocalcemic patients with CKD, phosphorus and
alcium intake similar to that administrated to
ur patients did not change FGF-23 levels. It
herefore seems less likely that phosphorus in-
ake caused the slight and transient decrease in
GF-23 levels in our patients.
Recently, it was shown in PTH–cyclin D1
ransgenic mice, a model for primary hyperpara-
hyroidism, that FGF-23 levels directly corre-
ated with serum PTH and inversely with serum
hosphorus levels. After parathyroidectomy,
GF-23 levels decreased in these mice, suggest-
ng a major role of PTH in the regulation of
erum FGF-23 levels.25 Our finding that intact
nd C-term FGF-23 levels decreased after cina-
alcet-mediated PTH reduction further supports
he hypothesis that PTH has a role in the regula-
ion of FGF-23. In our patients, FGF-23 levels
nly moderately decreased, whereas after total tarathyroidectomy, the decrease in FGF-23 lev-
ls was more pronounced in patients with CKD
nd secondary hyperparathyroidism26 or patients
ith primary hyperparathyroidism,5 probably be-
ause the cinacalcet-mediated PTH reduction
as only transient in our patients. Interestingly,
n the study by Isakova et al,24 urinary calcium
nd phosphorus excretion increased postprandial
n normal healthy volunteers and patients with
KD, whereas PTH levels increased only in
atients with CKD and thus may represent a
ovel mechanism of secondary hyperparathyroid-
sm. In our patients, cinacalcet decreased PTH
evels and urinary phosphorus excretion postpran-
ial and may blunt this suggested novel renal
ompensatory mechanism. We previously re-
orted that in our patients, 30 and 60 mg of
inacalcet decreased serum calcium levels and
ncreased urinary calcium excretion in the first 8
ours after cinacalcet administration. Lower se-
um calcium levels in patients with decreased
FR could increase serum phosphorus levels
hrough the combination of stimulated PTH secre-
ion and a decrease in calcium-phosphate prod-
ct. However, the phosphorus homeostasis in our
inacalcet-treated patients was influenced less
ikely by the normalization of serum calcium
evels because PTH levels decreased and calcium-
hosphate product was unchanged.
The relationship between different FGF-23
ssays was assessed in normophosphatemic indi-
iduals and patients with TIO.27 Similar to our
esults, high correlation was found between the
-term FGF-23 assay from Immutopics and in-
act FGF-23 assay from Kainos. However, in
atients with suspected and confirmed TIO, the
reatest sensitivity was found for the Kainos
ntact FGF-23 assay. Interestingly, all our pa-
ients had increased intact FGF-23 levels at any
ampling time comparing with the normal mean
f the assay (29.7 pg/mL), whereas C-term
GF-23 levels were not greater than the mean of
he assay (72.9 RU/mL) in 3, 5, and 4 patients at
tudy days 0, 14, and 28, respectively. The Immu-
opics FGF-23 assay detects C-term fragments
long with the biologically active molecule, and
hese fragments may accumulate in patients with
ecreased GFR, resulting in increased variabil-
ty. Although kidney function was stable in our
atients and despite the high correlation between
he 2 assays, the greater variability of the Immu-
t
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Serra, Wuhrmann, and Wüthrich1156opics assay may explain its decreased assay
ensitivity compared with the Kainos FGF-23
ssay in our patients with GFR less than 60
L/min 1.73 m2. Overall, our results confirm the
xcellent sensitivity of the Kainos intact FGF-23
ssay.
Once-daily administration of cinacalcet was
ufficient to normalize serum phosphorus levels.
nterestingly, patients on dialysis therapy with
idney function that is completely abolished show
decrease in serum phosphorus levels in re-
ponse to cinacalcet,28 suggesting a kidney-
ndependent effect of cinacalcet on serum phos-
horus levels. Serum phosphorus concentration
s regulated not only by renal reabsorption, but
lso by the interaction between renal absorption
nd exchange with the bone. Release of phospho-
us from the bone occurs as a consequence of
alcium homeostasis and is accompanied by
ovement of calcium in the same direction.
hosphorus also is released from the bone as a
onsequence of increased osteoclast activity that
s regulated by several hormones, including PTH
nd calcitonin. We previously showed that cina-
alcet treatment decreased PTH and increased
alcitonin levels, with both changes in favor of
ncreased bone formation.14 Furthermore, given
he calcium-lowering effect of cinacalcet and the
nchanged marker for bone resorption (deoxypyr-
dinoline-creatinine ratio), the phosphatemic ac-
ion of cinacalcet in kidney transplant recipients
s less likely to depend on a substantial release of
hosphorus from the bone.
A limitation of our study is that intestinal
hosphorus absorption was not determined. Pa-
ients were fasting 12 hours before study visits,
nd phosphorus intake was kept constant on the
tudy morning, but we cannot exclude that a
inacalcet-mediated change in intestinal phospho-
us absorption contributed to the phosphatemic
ction of cinacalcet. Second, factors regulating
ellular phosphorus uptake are not well defined.
cid-base changes can cause profound changes
n serum phosphorus levels by translocation of
hosphorus in and out of cells. We could show
hat acid-base status in our patients was un-
hanged. In addition to FGF-23, other phospha-
onins, such as frizzled-related protein 4 and
GF-7, could have influenced the phosphatemic
ction of cinacalcet.10,29 AIn conclusion, cinacalcet effectively corrected
nappropriate urinary phosphate wasting and nor-
alized serum phosphorus levels in renal allo-
raft recipients with hypophosphatemia caused
y persistent hyperparathyroidism. Overall, the
inacalcet-induced increase in renal phosphorus
eabsorption appears to result predominantly
hrough decreasing PTH levels.
ACKNOWLEDGEMENTS
We thank Simone Braun, MD, Julia Hofmann, and Chris-
ina Klemm, MD, for excellent technical assistance.
Support: This work was supported in part by an unre-
tricted research grant by Amgen Inc.
Financial Disclosure: None.
REFERENCES
1. Kempson SA, Lotscher M, Kaissling B, et al: Parathy-
oid hormone action on phosphate transporter mRNA and
rotein in rat renal proximal tubules. Am J Physiol 268:F784-
791, 1995
2. Ohkido I, Segawa H, Yanagida R, et al: Cloning, gene
tructure and dietary regulation of the type-IIc Na/Pi cotrans-
orter in the mouse kidney. Pflugers Arch 446:106-115, 2003
3. Shimada T, Mizutani S, Muto T, et al: Cloning and
haracterization of FGF23 as a causative factor of tumor-
nduced osteomalacia. Proc Natl Acad Sci U S A 98:6500-
505, 2001
4. Shimada T, Yamazaki Y, Takahashi M, et al: Vitamin D
eceptor-independent FGF23 actions in regulating phos-
hate and vitamin D metabolism. Am J Physiol Renal
hysiol 289:F1088-F1095, 2005
5. Kobayashi K, Imanishi Y, Miyauchi A, et al: Regula-
ion of plasma fibroblast growth factor 23 by calcium in
rimary hyperparathyroidism. Eur J Endocrinol 154:93-99,
006
6. Yamashita H, Yamashita T, Miyamoto M, et al: Fibro-
last growth factor (FGF)-23 in patients with primary hyper-
arathyroidism. Eur J Endocrinol 151:55-60, 2004
7. Gutierrez O, Isakova T, Rhee E, et al: Fibroblast
rowth factor-23 mitigates hyperphosphatemia but accentu-
tes calcitriol deficiency in chronic kidney disease. J Am Soc
ephrol 16:2205-2215, 2005
8. Larsson T, Nisbeth U, Ljunggren O, et al: Circulating
oncentration of FGF-23 increases as renal function declines
n patients with chronic kidney disease, but does not change
n response to variation in phosphate intake in healthy
olunteers. Kidney Int 64:2272-2279, 2003
9. Shigematsu T, Kazama JJ, Yamashita T, et al: Possible
nvolvement of circulating fibroblast growth factor 23 in the
evelopment of secondary hyperparathyroidism associated
ith renal insufficiency. Am J Kidney Dis 44:250-256, 2004
10. Pande S, Ritter CS, Rothstein M, et al: FGF-23 and
FRP-4 in chronic kidney disease and post-renal transplanta-
ion. Nephron Physiol 104:p23-p32, 2006
11. Evenepoel P, Naesens M, Claes K, et al: Tertiary
hyperphosphatoninism’ accentuates hypophosphatemia and
uppresses calcitriol levels in renal transplant recipients.
m J Transplant 7:1193-1200, 2007
h
n
I
c
r
4
c
r
5
t
p
r
e
p
8
i
h
p
m
t
m
p
D
t
r
c
w
6
c
h
d
t
M
m
e
r
m
N
e
2
n
S
t
2
N
w
g
f
Phosphatemic Effect of Cinacalcet 115712. Bhan I, Shah A, Holmes J, et al: Post-transplant
ypophosphatemia: Tertiary ‘hyper-phosphatoninism’? Kid-
ey Int 70:1486-1494, 2006
13. Fox J, Lowe SH, Petty BA, et al: NPS R-568: A type
I calcimimetic compound that acts on parathyroid cell
alcium receptor of rats to reduce plasma levels of parathy-
oid hormone and calcium. J Pharmacol Exp Ther 290:473-
79, 1999
14. Serra AL, Savoca R, Huber AR, et al: Effective
ontrol of persistent hyperparathyroidism with cinacalcet in
enal allograft recipients. Nephrol Dial Transplant 22:577-
83, 2007
15. Serra AL, Schwarz AA, Wick FH, et al: Successful
reatment of hypercalcemia with cinacalcet in renal trans-
lant recipients with persistent hyperparathyroidism. Neph-
ol Dial Transplant 20:1315-1319, 2005
16. El-Amm JM, Doshi MD, Singh A, et al: Preliminary
xperience with cinacalcet use in persistent secondary hyper-
arathyroidism after kidney transplantation. Transplantation
3:546-549, 2007
17. Serra AL, Braun SC, Starke A, et al: Pharmacokinet-
cs and pharmacodynamics of cinacalcet in patients with
yperparathyroidism after renal transplantation. Am J Trans-
lant 8:803-810, 2008
18. Srinivas TR, Schold JD, Womer KL, et al: Improve-
ent in hypercalcemia with cinacalcet after kidney transplan-
ation. Clin J Am Soc Nephrol 1:323-326, 2006
19. Kruse AE, Eisenberger U, Frey FJ, et al: The calcimi-
etic cinacalcet normalizes serum calcium in renal trans-
lant patients with persistent hyperparathyroidism. Nephrol
ial Transplant 20:1311-1314, 2005
20. Szczech LA: The impact of calcimimetic agents on
he use of different classes of phosphate binders: Results of
ecent clinical trials. Kidney Int Suppl 90:S46-S48, 2004 c21. Szwarc I, Argiles A, Garrigue V, et al: Cinacalcet
hloride is efficient and safe in renal transplant recipients
ith posttransplant hyperparathyroidism. Transplantation 82:
75-680, 2006
22. Charytan C, Coburn JW, Chonchol M, et al: Cinacal-
et hydrochloride is an effective treatment for secondary
yperparathyroidism in patients with CKD not receiving
ialysis. Am J Kidney Dis 46:58-67, 2005
23. Geller JL, Khosravi A, Kelly MH, et al: Cinacalcet in
he management of tumor-induced osteomalacia. J Bone
iner Res 22:931-937, 2007
24. Isakova T, Gutierrez O, Shah A, et al: Postprandial
ineral metabolism and secondary hyperparathyroidism in
arly CKD. J Am Soc Nephrol 19:615-623, 2008
25. Kawata T, Imanishi Y, Kobayashi K, et al: Parathy-
oid hormone regulates fibroblast growth factor-23 in a
ouse model of primary hyperparathyroidism. J Am Soc
ephrol 18:2683-2688, 2007
26. Sato T, Tominaga Y, Ueki T, et al: Total parathyroid-
ctomy reduces elevated circulating fibroblast growth factor
3 in advanced secondary hyperparathyroidism. Am J Kid-
ey Dis 44:481-487, 2004
27. Imel EA, Peacock M, Pitukcheewanont P, et al:
ensitivity of fibroblast growth factor 23 measurements in
umor-induced osteomalacia. J Clin Endocrinol Metab 91:
055-2061, 2006
28. Moe SM, Chertow GM, Coburn JW, et al: Achieving
KF-K/DOQI bone metabolism and disease treatment goals
ith cinacalcet HCl. Kidney Int 67:760-771, 2005
29. Carpenter TO, Ellis BK, Insogna KL, et al: Fibroblast
rowth factor 7: An inhibitor of phosphate transport derived
rom oncogenic osteomalacia-causing tumors. J Clin Endo-
rinol Metab 90:1012-1020, 2005
